Corindus Promotes Doug Teany to Chief Operating Officer

Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading
developer of precision vascular robotics, today announced that it
has appointed Douglas Teany, currently the company’s Senior Vice
President of R&D and Operations, to Chief Operating Officer, effective

Teany brought eighteen years of experience to Corindus, driving
operational excellence in the medical device and pharmaceutical
industries. He previously served as Vice President in Boston
Scientific’s development organization, responsible for strategy and
operations of its global clinical and preclinical research functions.
Teany has served in his current role at Corindus since March 2016. Since
joining, he accelerated the launch of Corindus’ second generation
CorPath GRX System, established a robust product and technology roadmap,
and effectively scaled production and operational capabilities. As Chief
Operating Officer, Teany will be responsible for leadership and
integration of the company’s Upstream Product Management, Research &
Development, Operations, Quality, and Field Service Engineering
functions. In this capacity, he will set direction for product
innovation and development, drive efficient production operations,
establish and maintain the company’s quality management system, and
ensure effectiveness of technical field support.

“This promotion is well deserved and a testament to the contributions
Doug and his team have made at Corindus,” stated Mark Toland, President
and Chief Executive Officer. “Under Doug’s leadership, we have made
tremendous strides in our technology development and he is uniquely
qualified to drive the company towards continued operational and
engineering excellence.”

“Corindus has a powerful vision for the future of vascular robotics,”
said Teany. “From remote treatment capabilities to procedures backed by
automation and artificial intelligence, the next several years will be
transformative for both Corindus and our customers. Our technical teams
are making steady progress toward realizing our goals while our
operational teams are well positioned for the growth that will follow. I
am incredibly energized to lead such a talented and capable team.”

About Corindus Vascular Robotics, Inc.

Vascular Robotics, Inc. is a global technology leader in
robotic-assisted vascular interventions. The company’s CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and percutaneous vascular procedures.
During the procedure, the interventional cardiologist sits at a
radiation-shielded workstation to advance guide catheters, stents, and
guidewires with millimeter-by-millimeter precision. The workstation
allows the physician greater control and the freedom from wearing heavy
lead protective equipment that causes musculoskeletal injuries. CorPath
GRX is the second generation robotic-assisted PCI technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities and
range of procedures that can be performed robotically. With the CorPath
System, Corindus Vascular Robotics brings robotic precision to
interventional procedures to help optimize clinical outcomes and
minimize the costs associated with complications of improper stent
placement during manual procedures. Corindus stands behind its product
with its unique $1,000 hospital credit “One Stent Program.” For
additional information, visit www.corindus.com,
and follow @CorindusInc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180619005201/en/